GI Dysmotility Article 2: Treating SIBO, Gastroparesis, and the Gut — Diet, Prokinetics, Antibiotics, DAO, and What It Means When Nothing Helps
If you have ME/CFS and gut symptoms, you are in the one system where you have direct agency — diet is a lever you can pull without a prescription, without a specialist, and without leaving your home. But the treatments beyond diet — SIBO antibiotics, prokinetics, elemental diet — require a prescriber, an understanding of the mechanism, and a plan for what a failure means.
This article explains the treatment architecture. For the conceptual background — what GI dysmotility and SIBO are, the three mechanisms, and the gut-problems-alone vs ME/CFS-with-gut-problems distinction — see the companion overview article.
1 First, a plain warning
Everything below is a conversation to have with a clinician, not self-medication. SIBO antibiotics and prokinetics are prescription medications. Elimination diets — especially prolonged low-FODMAP or low-histamine — risk malnutrition and should be supervised by a dietitian. Elemental diet requires medical supervision. DAO supplements are unregulated.
2 The treatment ladder
2.1 Diet: the first lever
Meal spacing — 4–5 hours between meals, no snacking. The migrating motor complex (MMC) only activates during fasting. In a person with impaired MMC, every snack resets the clock. Meal spacing is the simplest, lowest-cost non-pharmacological MMC support and requires no prescription, no dietitian, and no supplements. If meal spacing alone reduces bloating and early satiety within 2 weeks, you have identified a motility-dependent symptom component — and that tells you something useful about the mechanism.
Low-histamine elimination diet — 3–4 weeks of strict avoidance of high-histamine foods (aged, fermented, cured, tinned fish, shellfish, tomatoes, spinach, aubergine, avocado, alcohol), followed by structured reintroduction. If symptoms improve by >50% within 3–4 weeks, histamine is a contributor. If weight drops or nothing changes in that window, stop — prolonged restriction without benefit causes malnutrition and eating-disorder risk without justification (Comas-Basté et al. 2020).
Low-FODMAP — for the IBS-overlap subtype (bloating, alternating diarrhoea and constipation, pain relieved by bowel movements). Three phases: 4–6 week strict elimination, structured reintroduction of individual FODMAP groups, personalised maintenance. Requires a dietitian — the restriction phase is nutritionally inadequate if prolonged, and unsupervised FODMAP elimination can worsen dysbiosis by starving beneficial fibre-fermenting bacteria.
2.2 SIBO treatment
Rifaximin 550 mg three times daily for 14 days — first-line for hydrogen-predominant SIBO. It is non-absorbed (stays in the gut), has a low side-effect profile, and has trial evidence for IBS with SIBO. If methane is elevated (IMO — intestinal methanogen overgrowth), add neomycin 500 mg twice daily. Neomycin carries a black-box ototoxicity warning and is nephrotoxic, and it is partly absorbed even orally (~1–3%), so it is contraindicated in renal impairment and should only be used short-term with hearing/tinnitus and renal screening in mind — a real safety point, not a routine add-on. If hydrogen sulfide is suspected (rotten-egg-smelling gas, diarrhoea), metronidazole (typically 500 mg three times daily) or dietary sulfate reduction is more targeted — metronidazole causes a disulfiram-like reaction with alcohol and interacts with warfarin, so both must be flagged. SIBO recurs if the motility defect is not addressed — antibiotics alone are followed by a substantial recurrence rate (commonly reported around 44% within roughly 9 months, though estimates vary by study and definition), which is why a prokinetic to restore the MMC is usually the point.
Herbal antimicrobials — berberine, allicin (for methane), oregano oil, neem — are sometimes used against SIBO. One head-to-head study reported comparable normalisation rates to rifaximin (46% vs 34%), but this is a single-trial, small-sample comparison, not strong evidence of equivalence, and these compounds are not a substitute for a medically managed antibiotic course. They are available without prescription, but several cautions apply: berberine can lower blood pressure and interacts with CYP450 enzymes; oregano oil is caustic to the oesophagus if taken undiluted; and unregulated supplements vary in quality and standardisation, so a product purchased online is not the same dose or purity as the study material. If used, they should be discussed with a clinician and in no case taken to avoid a prescribed course of rifaximin.
Elemental diet — a liquid formula of pre-digested nutrients that requires no digestion, starving bacteria while feeding the patient. 14 days of exclusive elemental diet achieves 80–85% SIBO eradication — among the highest rates of any intervention — but palatability, cost, and the practical burden are significant barriers [Pimentel et al. (2004)](Rezaie et al. 2025). In severe ME/CFS, the elemental diet paradoxically may reduce burden (no cooking, no decision-making about food) while treating the SIBO.
Prokinetics — low-dose erythromycin (50 mg at bedtime, motilin agonist, stimulates gastric MMC), prucalopride (1–2 mg daily, 5-HT₄ agonist, stimulates small-bowel MMC), or metoclopramide (typically 5–10 mg before meals and at bedtime; the only FDA-approved gastroparesis drug, but it carries a real tardive dyskinesia risk, and the FDA limits continuous use to 12 weeks because the risk rises with cumulative exposure — it is not a long-term option). Prokinetics are not for acute SIBO treatment — they are for preventing recurrence after eradication, by restoring the MMC that keeps bacteria swept downstream.
2.3 Barrier and butyrate support
- Butyrate (sodium butyrate 600–1200 mg twice daily or tributyrin) — the primary energy source for colonocytes, stabiliser of tight junctions, and HDAC inhibitor that suppresses mast-cell degranulation by up to 90%.
- Zinc carnosine 75 mg twice daily — stabilises the gastric and intestinal mucosal barrier.
- L-glutamine 5 g daily — the primary fuel for enterocytes during small-intestinal barrier repair.
2.4 DAO supplementation
DAO enzyme capsules (derived from porcine kidney), taken 15 minutes before meals, degrade dietary histamine in the gut lumen. If post-meal flushing, tachycardia, and brain fog improve, histamine intolerance is suggested — though not definitively confirmed, because a response to DAO is also consistent with placebo or with a general reduction in gut symptoms, and DAO only addresses the dietary-histamine load, not endogenous mast-cell production. DAO is not a treatment for MCAS. It is a low-risk diagnostic-therapeutic agent that can be trialled alongside dietary changes.
3 Expected results
- Meal spacing works quickly or not at all. If 4–5 hour gaps between meals reduce bloating within 2 weeks, the MMC is functional and motility is the lever. If it does nothing, the MMC may be too impaired for meal spacing alone to restore it.
- The low-histamine diet is a 3–4 week diagnostic probe. If symptoms improve, continue with structured reintroduction. If nothing changes, stop the restriction — do not drift into long-term malnutrition.
- Rifaximin works within the 14-day course or not at all. If bloating, distension, and bowel habits normalise, SIBO was present. If nothing changes — and the breath test was positive — one honest possibility is a false-positive breath test (~30–40% rate).
- Prokinetics prevent recurrence, not acute SIBO. If SIBO recurs within 3 months of antibiotics, the MMC is not being maintained — add a prokinetic. If SIBO does not recur without prokinetics, the MMC recovered on its own.
- DAO is a diagnostic probe, not a long-term fix. If DAO supplementation improves post-meal symptoms, HIT is a likely contributor and dietary management is the strategy — though response can also reflect placebo. DAO supplementation is suggestive of the mechanism; it does not replace dietary histamine avoidance.
4 An example structured trial
This is an example to give your clinician something to work from — not a self-prescription.
Start with meal spacing: 4–5 hours between meals, no snacking. Reassess bloating and early satiety at 2 weeks. If improved, continue — you have a motility-dependent component.
Add the low-histamine diet for 4 weeks. Reassess at 4 weeks. If post-meal flushing, tachycardia, and brain fog improve by >50%, histamine is a contributor. If nothing changes, stop the diet — histamine is not the dominant mechanism.
If bloating, early satiety, and alternating bowel habits persist despite meal spacing, get a lactulose breath test. If hydrogen or methane is elevated, treat with rifaximin 550 mg TID ± neomycin 500 mg BID for 14 days. Reassess at 4 weeks post-treatment. If SIBO symptoms recur within 3 months, add a prokinetic (erythromycin 50 mg at bedtime). Reassess at 12 weeks. Stop the prokinetic if SIBO has not recurred at 6 months — the MMC may have recovered.
If all of the above fails and SIBO is confirmed on repeat testing, consider a 14-day elemental diet under medical supervision.
Only add one intervention at a time. Adding everything at once — meal spacing + low-histamine + rifaximin + prokinetic simultaneously — makes it impossible to know what helped.
5 What it means if the treatment does not help
One: SIBO treatment may fail because the breath test was a false positive. Breath tests have a ~30–40% false-positive rate, and the 2024 consensus statement’s “remains unproven” conclusion is a genuine epistemic limitation. If rifaximin and herbal antimicrobials produce no benefit, one honest possibility is that SIBO was never the problem — the symptoms had a different mechanism (visceral hypersensitivity, MCAS, rapid transit).
Two: the low-histamine diet may fail because histamine is not the problem. If 4 weeks of strict dietary histamine reduction produces no change, and DAO supplementation also fails, histamine is unlikely to be a major contributor — stop dietary restriction and look to other mechanisms.
Three: prokinetics may fail because the MMC is structurally damaged, not just slowed. If ICCs are destroyed by autoantibodies, not just functionally suppressed, a drug that stimulates residual ICC function may have limited effect. The distinction matters for expectations — prokinetics support residual function; they do not regenerate lost pacemaker cells.
Four: the gut may not be the dominant amplifier. If you have treated SIBO, eliminated histamine, restored butyrate, and taken prokinetics — and the fatigue, brain fog, and PEM are unchanged — the gut was a passenger, not a driver, in your specific case. That is honest and useful information. Stop pursuing gut-targeted treatments and move to the next amplifier.
Five: elemental diet may fail because the underlying cause was never the bacteria. Elemental diet removes all dietary substrate for bacterial fermentation — if 14 days of exclusive elemental diet produces no improvement, the symptoms were not bacterial-overgrowth-driven. They may be visceral hypersensitivity, MCAS, or rapid transit. That is a finding — the most aggressive SIBO treatment available has been tested and has failed, and the probability that SIBO is the dominant mechanism drops substantially.
6 The falsifiable predictions
- If mast-cell stabilisers (cromolyn, ketotifen) improve GI dysmotility independent of diet changes, mast-cell mediators are a direct motility brake, and stabilisers are upstream of prokinetics in the treatment algorithm.
- If butyrate supplementation reduces mast-cell degranulation markers (urinary methylhistamine, prostaglandin D₂ metabolite) in SIBO-positive ME/CFS, the butyrate-deficiency→mast-cell-disinhibition pathway is clinically relevant and the microbiome-mast-cell axis is a targetable mechanism.
- If prokinetics prevent SIBO recurrence in patients with normal ICC function (anti-CdtB/anti-vinculin negative) but fail in patients with positive anti-ICC antibodies, the ICC-damage mechanism is clinically actionable and antibody testing should guide prokinetic expectations.
7 What you can actually do
- Start with meal spacing. Four to five hours between meals, no snacking. This costs nothing, requires no prescription, and directly supports MMC function. If it helps, you have identified a motility-dependent symptom component.
- Trial a low-histamine diet for 4 weeks with a clear stop-date. If symptoms improve, histamine is relevant. If nothing changes, stop the restriction.
- Get a lactulose breath test, but read it critically. A positive test suggests SIBO; a negative test does not rule it out. Treat the clinical picture, not a borderline number.
- If SIBO is treated, add a prokinetic to prevent recurrence. Antibiotics clear the overgrowth; only restored MMC function prevents it from coming back.
- Consider DAO before meals as a diagnostic probe. Consistent DAO-related improvement suggests HIT; needing antihistamines as well suggests an additional endogenous mast-cell (MCAS) component; neither helping suggests histamine is not a major contributor. Treat each of these as a suggestive signal, not a proof — response can also reflect placebo or unrelated gut improvement.
- Accept that the gut is one amplifier among several. Treating it may reduce the total illness burden without fixing the energy crisis. That is not failure — it is accurate targeting in a multi-amplifier system.
8 The bottom line
GI dysmotility treatment in ME/CFS runs from meal spacing and low-histamine elimination through SIBO antibiotics and elemental diet to DAO, butyrate, and prokinetics. Diet is the first lever — the intervention the patient controls directly — and the pharmacology is supportive, not central (Loth 2026).
A failed trial of any one intervention tells you something specific — which mechanism is not dominant in your case — and that is useful information, not a personal failure. The structured-trial architecture (one intervention at a time, named endpoint, named stop-rule) is how you distinguish signal from noise in a multi-mechanism system.
For the comprehensive, fully-cited picture of how GI dysmotility and the gut microbiome are weighed among the many candidate mechanisms in ME/CFS, see (Loth 2026).